Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.40, for a total value of $717,600.00. Following the sale, the chief executive officer directly owned 850,347 shares in the company, valued at approximately $15,646,384.80. This represents a 4.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total value of $680,550.00.
• On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $41,242.36.

CeriBell Trading Down 0.6%

NASDAQ CBLL opened at $18.57 on Friday. The firm has a market cap of $698.97 million, a P/E ratio of -12.63 and a beta of 0.94. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. The stock’s 50-day moving average is $19.08 and its 200-day moving average is $17.58. CeriBell, Inc. has a one year low of $10.01 and a one year high of $24.33.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. Sell-side analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CBLL shares. BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group lifted their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CeriBell in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in CeriBell in the 2nd quarter valued at approximately $1,054,000. Emerald Mutual Fund Advisers Trust grew its stake in CeriBell by 58.2% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after purchasing an additional 57,175 shares in the last quarter. CenterBook Partners LP grew its stake in CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares in the last quarter. Peregrine Capital Management LLC grew its stake in CeriBell by 7.7% in the third quarter. Peregrine Capital Management LLC now owns 367,945 shares of the company’s stock valued at $4,228,000 after purchasing an additional 26,286 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in CeriBell by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after purchasing an additional 31,177 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.